Name: MLN9708
Price: 268.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    MLN9708, also known as ixazomib, is a second-generation small-molecule proteasome inhibitor. It is a citrate ester that immediately hydrolyzes to its biologically active form MLN2238 upon exposure to aqueous solutions or plasma. MLN9708 was selected from a large pool of boron-containing proteasome inhibitors based on a physicochemical profile that was distinct from bortezomib. MLN9708 has a shorter 20S proteasome dissociation half-life than bortezomib, which is demonstrated to play an important role in its improved tissue distribution.
- Properties
  - Alternative Name
    
    MLN-9708, MLN 9708; [(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]boronic acid
    
    CAS Number
    
    1201902-80-8
    
    Molecular Formula
    
    C20H23BCl2N2O9
    
    Molecular Weight
    
    517.1
    
    Purity
    
    98.00%
    
    Solubility
    
    insoluble in H2O; ≥20.85 mg/mL in DMSO; ≥4.56 mg/mL in EtOH with gentle warming and ultrasonic
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only
- Reference
  - 1. Mañas A, Chen W, et al. "BaxΔ2 sensitizes colorectal cancer cells to proteasome inhibitor-induced cell death." Biochem Biophys Res Commun. 2018 Jan 29;496(1):18-24. PMID:29291406
    2. Li H, Chen Z, et al. "Novel proteasome inhibitor ixazomib sensitizes neuroblastoma cells to doxorubicin treatment." Sci Rep. 2016 Sep 30;6:34397. PMID:27687684
    3. Wang H, Yu Y, et al. "Next-generation proteasome inhibitor MLN9708 sensitizes breast cancer cells to doxorubicin-induced apoptosis." Sci Rep. 2016 May 24;6:26456. PMID:27217076

MLN9708

MLN9708

Background

We Also Recommend

CEP-18770

MLN2238

Salinosporamide A (NPI-0052, Marizomib)